Everything on Pharma Innovation

Novo Nordisk’s licensing of Nanexa’s PharmaShell technology validates the value of extended-release drug delivery platforms. The deal includes over €1 billion in potential payments, highlighting the strategic importance of biotech coatings.

Impact: This partnership could accelerate the development of more effective drugs, benefiting both companies and potentially setting a new standard for drug delivery technologies.

— from BASF-Evonik Merger, BIC Cannabis Pivot, and Pharma Breakthroughs · OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News· Sep 28, 2026